219 related articles for article (PubMed ID: 37384818)
21. Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy.
Ramesh A; Kumar S; Nguyen A; Brouillard A; Kulkarni A
Nanoscale; 2020 Jan; 12(3):1875-1885. PubMed ID: 31903467
[TBL] [Abstract][Full Text] [Related]
22. Design of Light-Activated Nanoplatform through Boosting "Eat Me" Signals for Improved CD47-Blocking Immunotherapy.
Lu Y; Gong Y; Zhu X; Dong X; Zhu D; Ma G
Adv Healthc Mater; 2022 May; 11(10):e2102712. PubMed ID: 34981660
[TBL] [Abstract][Full Text] [Related]
23. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
24. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
25. Intracellular Magnetic Hyperthermia Enables Concurrent Down-Regulation of CD47 and SIRPα To Potentiate Antitumor Immunity.
Wang S; Jiao W; Yan B; Liu X; Tang Q; Zhang Y; Liang C; Wang X; Lyu Y; Fan H; Liu X
Nano Lett; 2024 Mar; 24(9):2894-2903. PubMed ID: 38407042
[TBL] [Abstract][Full Text] [Related]
26. Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy.
Dong Q; Han D; Li B; Yang Y; Ren L; Xiao T; Zhang J; Li Z; Yang H; Liu H
Int J Biol Macromol; 2023 Jun; 240():124342. PubMed ID: 37030459
[TBL] [Abstract][Full Text] [Related]
27. Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles.
Rao L; Zhao SK; Wen C; Tian R; Lin L; Cai B; Sun Y; Kang F; Yang Z; He L; Mu J; Meng QF; Yao G; Xie N; Chen X
Adv Mater; 2020 Nov; 32(47):e2004853. PubMed ID: 33089578
[TBL] [Abstract][Full Text] [Related]
28. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
29. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
30. Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy.
Yang Y; Wu H; Yang Y; Kang Y; He R; Zhou B; Guo H; Zhang J; Li J; Ge C; Wang T
Mol Ther Oncolytics; 2023 Dec; 31():100747. PubMed ID: 38046893
[TBL] [Abstract][Full Text] [Related]
31. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal.
Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J
Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081
[No Abstract] [Full Text] [Related]
32. CD47/SIRPα axis: bridging innate and adaptive immunity.
van Duijn A; Van der Burg SH; Scheeren FA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
[TBL] [Abstract][Full Text] [Related]
33. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
34. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
36. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
[TBL] [Abstract][Full Text] [Related]
37. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
38. CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity.
Tang Z; Zhong MC; Qian J; Galindo CC; Davidson D; Li J; Zhao Y; Hui E; Veillette A
Nat Immunol; 2023 Dec; 24(12):2032-2041. PubMed ID: 37945822
[TBL] [Abstract][Full Text] [Related]
39. The development of small-molecule inhibitors targeting CD47.
Yu WB; Ye ZH; Chen X; Shi JJ; Lu JJ
Drug Discov Today; 2021 Feb; 26(2):561-568. PubMed ID: 33197622
[TBL] [Abstract][Full Text] [Related]
40. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
